UBS Maintains Neutral on Accendra Health, Raises Price Target to $4.5

Benzinga Newsdesk www.benzinga.com Positive 63.3%

Neg 0% Neu 0% Pos 63.3%

UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and raises the price target from $3 to $4.5.